Merck, Eisai Get FDA OK of Welireg/Lenvima Combo in Kidney Cancer
By Colin Kellaher
Merck and Eisai have won U.S. Food and Drug Administration approval of the dual oral regimen of Merck's Welireg plus both companies' Lenvima in certain patients with the most common type of kidney cancer.
The companies on Friday said the green light covers the combination in adults with advanced renal cell carcinoma with a clear cell component following a programmed death receptor-1 or programmed death-ligand 1 inhibitor.
Welireg plus Lenvima is the first approved combination of a hypoxia-inducible factor-2 alpha inhibitor and a multi-targeted vascular endothelial growth factor receptor tyrosine kinase inhibitors for these patients, the companies said.
Rahway, N.J., drugmaker Merck and Tokyo-based Eisai formed a collaboration in 2018 to jointly develop, manufacture and commercialize Lenvima, which Eisai discovered.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 25, 2026 07:19 ET (11:19 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States